Year All20252024202320222021202020192018201720162015201420122011 Jul 29, 2021 Ardelyx Receives Complete Response Letter from U.S. FDA for New Drug Application for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis Jul 19, 2021 Ardelyx Provides Regulatory Update on New Drug Application for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis Jun 7, 2021 Ardelyx Announces Presentations at ERA-EDTA Virtual Congress 2021 May 25, 2021 Ardelyx to Present at the Jefferies 2021 Virtual Healthcare Conference May 6, 2021 Ardelyx Reports First Quarter 2021 Financial Results and Recent Business Highlights Apr 29, 2021 Ardelyx Announces Extension of the PDUFA Review Period for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis Apr 16, 2021 Ardelyx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Apr 14, 2021 Ardelyx Collaboration Partner, Kyowa Kirin, Announces Initiation of Phase 3 Clinical Studies of Tenapanor for Hyperphosphatemia in Japan Apr 12, 2021 Ardelyx Announces Upcoming Data Presentation at ISN World Congress of Nephrology 2021 Mar 30, 2021 Ardelyx Announces Poster Presentations, Educational Symposium, and Exhibitor Showcase at National Kidney Foundation 2021 Virtual Spring Clinical Meetings